001     164588
005     20230915090554.0
024 7 _ |a pmc:PMC9136623
|2 pmc
024 7 _ |a 10.1001/jamanetworkopen.2022.13875
|2 doi
024 7 _ |a pmid:35616942
|2 pmid
024 7 _ |a altmetric:128907980
|2 altmetric
037 _ _ |a DZNE-2022-01137
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Schwarz, Claudia
|b 0
245 _ _ |a Effects of Spermidine Supplementation on Cognition and Biomarkers in Older Adults With Subjective Cognitive Decline: A Randomized Clinical Trial.
260 _ _ |a Chicago, Ill.
|c 2022
|b American Medical Association
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1654771625_6362
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a (CC BY)
520 _ _ |a Developing interventions against age-related memory decline and for older adults experiencing neurodegenerative disease is one of the greatest challenges of our generation. Spermidine supplementation has shown beneficial effects on brain and cognitive health in animal models, and there has been preliminary evidence of memory improvement in individuals with subjective cognitive decline.To determine the effect of longer-term spermidine supplementation on memory performance and biomarkers in this at-risk group.This 12-month randomized, double-masked, placebo-controlled phase 2b trial (the SmartAge trial) was conducted between January 2017 and May 2020. The study was a monocenter trial carried out at an academic clinical research center in Germany. Eligible individuals were aged 60 to 90 years with subjective cognitive decline who were recruited from health care facilities as well as through advertisements in the general population. Data analysis was conducted between January and March 2021.One hundred participants were randomly assigned (1:1 ratio) to 12 months of dietary supplementation with either a spermidine-rich dietary supplement extracted from wheat germ (0.9 mg spermidine/d) or placebo (microcrystalline cellulose). Eighty-nine participants (89%) successfully completed the trial intervention.Primary outcome was change in memory performance from baseline to 12-month postintervention assessment (intention-to-treat analysis), operationalized by mnemonic discrimination performance assessed by the Mnemonic Similarity Task. Secondary outcomes included additional neuropsychological, behavioral, and physiological parameters. Safety was assessed in all participants and exploratory per-protocol, as well as subgroup, analyses were performed.A total of 100 participants (51 in the spermidine group and 49 in the placebo group) were included in the analysis (mean [SD] age, 69 [5] years; 49 female participants [49%]). Over 12 months, no significant changes were observed in mnemonic discrimination performance (between-group difference, -0.03; 95% CI, -0.11 to 0.05; P = .47) and secondary outcomes. Exploratory analyses indicated possible beneficial effects of the intervention on inflammation and verbal memory. Adverse events were balanced between groups.In this randomized clinical trial, longer-term spermidine supplementation in participants with subjective cognitive decline did not modify memory and biomarkers compared with placebo. Exploratory analyses indicated possible beneficial effects on verbal memory and inflammation that need to be validated in future studies at higher dosage.ClinicalTrials.gov Identifier: NCT03094546.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Spermidine
|0 U87FK77H25
|2 NLM Chemicals
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Biomarkers
|2 MeSH
650 _ 2 |a Cognition: physiology
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: drug therapy
|2 MeSH
650 _ 2 |a Dietary Supplements
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Inflammation
|2 MeSH
650 _ 2 |a Neurodegenerative Diseases
|2 MeSH
650 _ 2 |a Spermidine: pharmacology
|2 MeSH
650 _ 2 |a Spermidine: therapeutic use
|2 MeSH
700 1 _ |a Benson, Gloria S
|b 1
700 1 _ |a Horn, Nora
|b 2
700 1 _ |a Wurdack, Katharina
|b 3
700 1 _ |a Grittner, Ulrike
|b 4
700 1 _ |a Schilling, Ralph
|b 5
700 1 _ |a Märschenz, Stefanie
|b 6
700 1 _ |a Köbe, Theresa
|b 7
700 1 _ |a Hofer, Sebastian J
|b 8
700 1 _ |a Magnes, Christoph
|b 9
700 1 _ |a Stekovic, Slaven
|b 10
700 1 _ |a Eisenberg, Tobias
|b 11
700 1 _ |a Sigrist, Stephan
|0 P:(DE-2719)2811106
|b 12
|u dzne
700 1 _ |a Schmitz, Dietmar
|0 P:(DE-2719)2810725
|b 13
|u dzne
700 1 _ |a Wirth, Miranka
|0 P:(DE-2719)2814122
|b 14
|u dzne
700 1 _ |a Madeo, Frank
|b 15
700 1 _ |a Flöel, Agnes
|0 P:(DE-2719)2812683
|b 16
|e Last author
|u dzne
773 _ _ |a 10.1001/jamanetworkopen.2022.13875
|g Vol. 5, no. 5, p. e2213875 -
|0 PERI:(DE-600)2931249-8
|n 5
|p e2213875
|t JAMA network open
|v 5
|y 2022
|x 2574-3805
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/164588/files/Effects%20of%20Spermidine%20Supplementation%20on%20Cognition%20and%20Biomarkers%20in%20Older%20Adults%20With%20Subjective%20Cognitive%20Decline.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/164588/files/Effects%20of%20Spermidine%20Supplementation%20on%20Cognition%20and%20Biomarkers%20in%20Older%20Adults%20With%20Subjective%20Cognitive%20Decline.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:164588
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 12
|6 P:(DE-2719)2811106
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 13
|6 P:(DE-2719)2810725
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2814122
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 16
|6 P:(DE-2719)2812683
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-03
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-03
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-02-03
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-02-03
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)
|0 LIC:(DE-HGF)CCBYNCNDNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-02-03
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b JAMA NETW OPEN : 2021
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-10-18T13:36:16Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-10-18T13:36:16Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-10-18T13:36:16Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-16
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b JAMA NETW OPEN : 2021
|d 2022-11-16
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research Rostock /Greifswald
|x 0
920 1 _ |0 I:(DE-2719)1710011
|k AG Wirth
|l Brain aging: Biomarkers, lifestyle factors and prevention of dementia
|x 1
920 1 _ |0 I:(DE-2719)1710008
|k AG Donix
|l Clinical planning and intersite group
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a I:(DE-2719)1710011
980 _ _ |a I:(DE-2719)1710008
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21